换一批
换一批Anti-EFNA4 Calicheamicin Conjugates Effectively Target Triple-Negative Breast and Ovarian Tumor-Initiating Cells to Result in Sustained Tumor Regressions.
第一作者：
Marc,Damelin
第一单位：
Pfizer, Inc., Pearl River, New York. scott.dylla@stemcentrx.com marc.damelin@pfizer.com.
作者：
主题词
氨基糖苷类(Aminoglycosides);动物(Animals);抗体, 单克隆, 鼠源性(Antibodies, Monoclonal, Murine-Derived);抗原, 肿瘤(Antigens, Neoplasm);细胞系, 肿瘤(Cell Line, Tumor);DNA(DNA);药物设计(Drug Design);烯二炔类(Enediynes);膜附着型配体A4(Ephrin-A4);女(雌)性(Female);基因表达谱(Gene Expression Profiling);基因表达调控, 肿瘤(Gene Expression Regulation, Neoplastic);HEK293细胞(HEK293 Cells);人类(Humans);小鼠(Mice);小鼠, 近交NOD(Mice, Inbred NOD);小鼠, SCID(Mice, SCID);肿瘤干细胞(Neoplastic Stem Cells);卵巢肿瘤(Ovarian Neoplasms);前瞻性研究(Prospective Studies);随机分配(Random Allocation);治疗结果(Treatment Outcome);异种移植模型抗肿瘤试验(Xenograft Model Antitumor Assays)
DOI
10.1158/1078-0432.CCR-15-0695
PMID
26015513
发布时间
2015-09-16
- 浏览23
Clinical cancer research
4165-73页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
